
Overview
Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs.
Dr. Hann is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.
Dr. Hann is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 93 peer reviewed articles and participating in 7 clinical trials. Dr. Hann is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
10803 Falls Road, Pavilion III STE 1500, Lutherville, MD 21093
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, Baltimore, MD 21224
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
6 Clinical Trials
Stoler Outpatient Cancer Clinic
Taofeek Owonikoko is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine. Dr. Holdhoff is currently accepting new patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner-Johnston is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner-Johnston is currently accepting new patients.
Frequently Asked Questions about Dr. Christine L. Hann
How do I make an appointment with Dr. Christine L. Hann?
You can book an appointment with Dr. Christine L. Hann by calling their office at 410-955-8964. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Christine L. Hann a top-rated expert for Small Cell Lung Cancer (SCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christine L. Hann is classified as an Elite expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Christine L. Hann specialize in?
While Dr. Christine L. Hann is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Christine L. Hann participate in research or clinical trials?
Yes. Dr. Christine L. Hann has published 93 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Christine L. Hann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Christine L. Hann accept my insurance?
Dr. Christine L. Hann accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 410-955-8964 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Lung CancerDr. Hann isElite. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Hann isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Hann isDistinguished. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Hann isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Hann isDistinguished. Learn about Lung Adenocarcinoma.
- Neuroendocrine TumorDr. Hann isDistinguished. Learn about Neuroendocrine Tumor.
- Pleuropulmonary BlastomaDr. Hann isDistinguished. Learn about Pleuropulmonary Blastoma.
- Squamous Cell Lung CarcinomaDr. Hann isDistinguished. Learn about Squamous Cell Lung Carcinoma.
- Thymic Epithelial TumorDr. Hann isDistinguished. Learn about Thymic Epithelial Tumor.
- Advanced
- ChordomaDr. Hann isAdvanced. Learn about Chordoma.
- Familial Pancreatic CancerDr. Hann isAdvanced. Learn about Familial Pancreatic Cancer.
- Pancreatic CancerDr. Hann isAdvanced. Learn about Pancreatic Cancer.
- Experienced
- AstrocytomaDr. Hann isExperienced. Learn about Astrocytoma.
- Brain TumorDr. Hann isExperienced. Learn about Brain Tumor.
- Embryonal Tumor with Multilayered Rosettes
- Familial Prostate CancerDr. Hann isExperienced. Learn about Familial Prostate Cancer.
- Febrile NeutropeniaDr. Hann isExperienced. Learn about Febrile Neutropenia.
- Gastroesophageal Junction CancerDr. Hann isExperienced. Learn about Gastroesophageal Junction Cancer.
- GlioblastomaDr. Hann isExperienced. Learn about Glioblastoma.
- GliomaDr. Hann isExperienced. Learn about Glioma.
- Gliomatosis CerebriDr. Hann isExperienced. Learn about Gliomatosis Cerebri.
- MelanomaDr. Hann isExperienced. Learn about Melanoma.
- MesotheliomaDr. Hann isExperienced. Learn about Mesothelioma.
- Metastatic Brain TumorDr. Hann isExperienced. Learn about Metastatic Brain Tumor.
- Metastatic Uveal MelanomaDr. Hann isExperienced. Learn about Metastatic Uveal Melanoma.
- NeuroblastomaDr. Hann isExperienced. Learn about Neuroblastoma.
- Olfactory NeuroblastomaDr. Hann isExperienced. Learn about Olfactory Neuroblastoma.
- Posterior Fossa TumorDr. Hann isExperienced. Learn about Posterior Fossa Tumor.
- Primitive Neuroectodermal Tumor (PNET)
- ThrombocytopeniaDr. Hann isExperienced. Learn about Thrombocytopenia.

